Pulmonary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
NYU Rory Meyers College of Nursing, New York, New York, USA.
Cancer Med. 2024 Nov;13(21):e7198. doi: 10.1002/cam4.7198.
Fatigue and sleep disorders are prevalent in cancer patients. Obstructive sleep apnea (OSA) commonly causes excessive daytime sleepiness (EDS) and fatigue. We hypothesize that treating cancer patients with OSA using positive airway pressure (PAP) will improve EDS and fatigue.
A retrospective chart review of sleep clinic visits of cancer patients with newly diagnosed OSA was performed. Epworth Sleepiness Scale (ESS) and fatigue reported at baseline and within 6 months of starting PAP therapy were compared between PAP-adherent and PAP-non-adherent patients.
65 cancer patients with OSA and ESS >10 were recommended PAP therapy, including 45 patients with fatigue. 29 patients pursued PAP therapy with 79% (n = 23) adherent at follow-up. The median baseline apnea hypopnea index (AHI) for OSA was 24.0 (interquartile range [IQR] 14.3, 32.3) and 23.8 (IQR 10.1, 42.8) events/hour among PAP-adherent and PAP-non-adherent patients, respectively (p = 0.90). Median baseline ESS was 14.0 (IQR 12.0, 17.0) among adherent and 17.0 (IQR 11.0, 17.3) among non-adherent patients (p = 0.73). The median ESS at follow-up of the adherent and non-adherent groups was 8.0 (IQR 6.0, 10.0) and 11.0 (IQR 8.0, 15.8), respectively (p = 0.08). Median ESS change was -5.0 (IQR -7.0, -4.0) in PAP adherent patients and -2.5 (IQR -5.25, -1.50) in PAP-non-adherent patients (p = 0.07). When the groups are examined separately, the median change in the PAP-adherent group was highly significant (p = 0.001), while the ESS median change in the PAP-non-adherent group was considerably less (p = 0.04). 17 out of the 21 PAP-adherent patients reporting fatigue at baseline indicated improvement at follow-up.
PAP therapy for OSA in cancer patients improves EDS and fatigue. Larger studies are necessary to evaluate the efficacy of PAP in improving fatigue in this population.
疲劳和睡眠障碍在癌症患者中很常见。阻塞性睡眠呼吸暂停(OSA)通常会导致日间嗜睡(EDS)和疲劳。我们假设使用正压通气(PAP)治疗 OSA 的癌症患者会改善 EDS 和疲劳。
对新诊断为 OSA 的睡眠诊所就诊的癌症患者进行了回顾性图表审查。比较了 ESS (Epworth 嗜睡量表)和疲劳在基线和开始 PAP 治疗后 6 个月的报告,分别在 PAP 依从性和非依从性患者之间进行比较。
65 名 OSA 合并 ESS >10 的癌症患者被推荐 PAP 治疗,其中 45 名患者有疲劳。29 名患者接受了 PAP 治疗,其中 79%(n=23)在随访时依从。OSA 的中位基线呼吸暂停低通气指数(AHI)分别为 PAP 依从性患者 24.0(IQR 14.3,32.3)和 23.8(IQR 10.1,42.8)事件/小时(p=0.90)。依从性患者的中位基线 ESS 为 14.0(IQR 12.0,17.0),而非依从性患者的 ESS 为 17.0(IQR 11.0,17.3)(p=0.73)。依从性组和非依从性组的中位随访 ESS 分别为 8.0(IQR 6.0,10.0)和 11.0(IQR 8.0,15.8)(p=0.08)。PAP 依从性患者的 ESS 中位变化为-5.0(IQR -7.0,-4.0),PAP 非依从性患者的 ESS 中位变化为-2.5(IQR -5.25,-1.50)(p=0.07)。当分别检查两组时,PAP 依从性组的中位变化具有统计学意义(p=0.001),而非依从性组的 ESS 中位变化则不太明显(p=0.04)。21 名基线报告疲劳的 PAP 依从性患者中有 17 名在随访时表示有所改善。
在癌症患者中,使用 PAP 治疗 OSA 可改善 EDS 和疲劳。需要更大规模的研究来评估 PAP 在改善该人群疲劳方面的疗效。